GGTI-297, with the CAS number 181045-83-0, is a small molecule inhibitor primarily known for its role in targeting the enzyme geranylgeranyltransferase I (GGTase I). This enzyme is crucial in the post-translational modification of proteins, particularly in the prenylation of small GTPases, which are involved in various cellular processes including signal transduction and cell growth. GGTI-297 has been studied for its potential therapeutic applications, particularly in cancer treatment, as it may disrupt the signaling pathways that promote tumor growth and survival. The compound is characterized by its ability to selectively inhibit GGTase I, leading to the prevention of protein prenylation, which can result in altered cellular functions. Additionally, GGTI-297 has been evaluated in preclinical studies for its efficacy and safety profile, contributing to the understanding of its potential as a therapeutic agent in oncology. As with many experimental compounds, further research is necessary to fully elucidate its pharmacological properties and clinical applications.

GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).

GGTI-297

181045-83-0: GGTI-297, with the CAS number 181045-83-0, is a small molecule inhibitor primarily known for its role in targeting the enzyme geranylgeranyltransferase I (GGTase I). This enzyme is crucial in the post-translational modification of proteins, particularly in the prenylation of small GTPases, which are involved in various cellular processes including signal transduction and cell growth. GGTI-297 has been studied for its potential therapeutic applications, particularly in cancer treatment, as it may disrupt the signaling pathways that promote tumor growth and survival. The compound is characterized by its ability to selectively inhibit GGTase I, leading to the prevention of protein prenylation, which can result in altered cellular functions. Additionally, GGTI-297 has been evaluated in preclinical studies for its efficacy and safety profile, contributing to the understanding of its potential as a therapeutic agent in oncology. As with many experimental compounds, further research is necessary to fully elucidate its pharmacological properties and clinical applications.

CAS 181045-83-0

GGTI-297

GGTI-297

Ref: TM-T70157